IL-15 and IL-21 remodeling of latency III gene expression in newly infected primary human B cells.

Abstract

(A) Immunoblot analysis of WCL from primary human B cells at the indicated days post infection (DPI) by the Akata EBV strain. (B) Immunoblot analysis of WCL from primary human B cells at 7 DPI, which were then mock treated or treated with the indicated cytokines for six days. (C) Immunoblot analysis of WCL from primary B cells that were treated with DMSO or JAKi (200 ng/ml) for two days at 4, 7 or 10 DPI. GM12878 WCL was included as a control. (D) Primary human B-cell transformation assay characterizing effects of DMSO vs JAKi (200 ng/ml) treatment on primary human B-cell outgrowth following infection by Akata EBV. Fitted non-linear regression curves are presented as mean ± SD from n = 3 replicates, *p p < 0.01. Blots are representative of n = 3 replicates. Cytokines were used at 100 ng/ml.</p